Skip to main content

Table 1 Summary of cases in which patients developed primary hepatic neuroendocrine carcinoma recurrence following surgical resection

From: Primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy: a case report

First author Year age sex Tumor size (cm) Solitary (yes/no) Treatment before surgery Recurrence (months) Site of recurrence Treatment after recurrence Survival (months)
Hsueh 1983 8 F 17 Yes Chemotherapy None None None 4
Zancotani 1996 56 M 5 Yes None 3 Liver None 5
Pilichowska 1999 57 M 8.2 Yes None ND Liver None 16
Ishida 2003 72 M 3 Yes None ND ND None ND
Garcia 2006 50 M 5 Yes None 4 Liver TACE, Chemotherapy 16
Yang 2009 65 M 7.5 Yes None 3 Liver None 12
56 M ND No None None None ND 36.9
68 F ND No None None None ND 18
51 F ND No Chemotherapy 6.2 ND ND 15.2
Akahoshi 2010 64 M 1.5 Yes None None None ND 3
Huang 2010 51 M ND No TACE 48 Liver ND 107
34 M ND No TACE None None ND 98
52 F ND No None 5 Liver ND 47
59 M ND No None None None None 34
54 M ND No None None None None 24
43 M ND No None None None None 15
50 F ND No None 5 Liver ND 14
37 M ND No None 1 Liver PEIT 13
58 F ND No None 39 ND ND 148
56 F ND No None 5 Liver ND 33
50 M ND No None 3 Liver ND 12
Chan Hyuk 2012 51 F ND No Chemotherapy None ND ND 36.9
68 F ND No None None ND ND 18
51 F ND No Chemotherapy 6.2 ND ND 15.2
Shinkawa 2013 73 M 5 Yes None 4 Bone, LN ND 6
Kim 2013 67 F 9 Yes None None None None 3
Kano 2014 73 M 3 Yes None 6 Liver Chemotherapy 10
Sotiropoul 2014 19 F 27 Yes None None None None 24
Aboelene 2014 51 M 20 Yes None None None None 6
Choi 2016 72 M 2.2 Yes None 6 Liver Chemotherapy 4
Nakatake 2017 62 M 5 Yes None 3 LN Chemotherapy 24
Harada 2017 69 F 3.5 Yes None 1 Liver, Lung Chemotherapy 19
Xin 2020 64 F 1.8 Yes None ND ND None 5
Yusuke 2021 78 M 6.6 Yes None 4 LN Chemotherapy 4
  1. TACE transarterial chemoembolization, F female, M male, ND not described, LN lymph node